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32Objective: BioGlue (CryoLife, Europa Ltd, Surrey, UK) is effective in reducing alveolar air leak after pulmonary
resection. However, concerns exist regarding the use of bovine-derived products. Vivostat (Vivostat A/S, Alle-
roed, Denmark) is an autologous fibrin sealant that confers certain advantages. It shows superior elastic properties,
a faster absorption time, and the absence of risk of transmission of blood-borne diseases.
Methods: We conducted a randomized, single blind controlled study to compare BioGlue and Vivostat in the
control of postoperative air leak. Primary endpoints were duration of air leak, time to intercostal drain removal,
and length of hospital stay. Secondary endpoints related to postoperative complications.
Results:Between December 2005 and December 2007, 103 patients were randomized. The analysis included 102
patients; 67% were male. Median age was 56  19 years. Indications for surgery were primary lung cancer in 41
patients (40%), secondary malignancy in 48 patients (47%), carcinoid in 6 patients (6%), and 7 patients underwent
surgery for benign disease (7%). Bilobectomy was performed in 2 patients (2%), lobectomy in 41 patients (40%),
lobectomy with lesser resection in 3 patients (3%), segmentectomy in 16 patients (16%), precision excision in 34
patients (33%), and 6 patients underwent other resections (6%). Median duration of air leak was 3 (0–32) days
versus 2 (0–33) days for patients who received BioGlue and Vivostat, respectively (P¼ .677). Time to intercostal
drain removal was 5 (1–32) days in the BioGlue group compared with 5 (1–34) days for the Vivostat group
(P ¼ .473). Median hospital stay was 8 (3–22) days versus 7 (2–29) days for the BioGlue and Vivostat groups,
respectively (P ¼ .382). There was no significant difference in the incidence of complications between the
2 groups (20 patients receiving BioGlue versus 19 patients receiving Vivostat, P ¼ .839).
Conclusions: There were no significant differences in the 3 clinical outcome measures of duration of air leak,
time to intercostal drain removal, and length of hospital stay in those patients receiving BioGlue or Vivostat.
Given the inherent advantages of our institutional preference is to use Vivostat in the control of postoperative
air leaks after pulmonary resection. (J Thorac Cardiovasc Surg 2010;140:32-8)Prolonged alveolar air leak after thoracotomy is defined as
an air leak that lasts more than 7 days.1 Its prevalence is
greater than 15% and it may result in complications, includ-
ing longer duration of intercostal drainage, increased immo-
bility, and greater postoperative pain.2 Longer hospital stays
and increased costs ensue.3 Moreover, these patients are at
risk of serious secondary complications, including empyema
and thromboembolic events.4
A previous randomized controlled trial conducted at the
Royal Brompton Hospital was the first to show clear benefits
in all 3 clinically relevant end points of reduced duration of
air leak, earlier chest drain removal, and shorter hospital
stay.5 In this previous study, BioGlue (CryoLife, Europa
Ltd, Surrey, UK) was compared with no sealant. BioGluee Department of Thoracic Surgery, Royal Brompton Hospital, London, United
om.
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The Journal of Thoracic and Cardiovascular Surgeis a surgical sealant consisting of bovine serum albumin
and glutaraldehyde.
However, BioGlue confers certain disadvantages. It has
a rigid, inelastic nature that does not expandwith the underly-
ing lung. Its non-autologous nature may make a foreign body
reaction more likely,6 and its absorption time of 2 years may
increase the possibility of infection7 and toxicity.8 Generic
concerns also exist regarding the potential risk of transmis-
sion of blood-borne diseases with bovine-derived products.
The Vivostat System (Vivostat A/S, Alleroed, Denmark)
is a system for the preparation and application of a sealant
made from a patient’s own blood. The Vivostat system pro-
duces a sealant that has superior elastic properties and a faster
absorption time9 and carries none of the generic concerns
associated with bovine products. If as effective, these inher-
ent advantages, would commend its use.
A randomized study evaluating the use of the Vivostat
System in eliminating air leak in thoracic surgery found
that the Vivostat sealant reduced air leak after lobectomy
compared with conventional measures alone.10
The aim of this study was to determine the relative effec-
tiveness of BioGlue and Vivostat in the reduction of postop-
erative air leak.ry c July 2010
Abbreviation and Acronym
POD ¼ postoperative day
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Participants
Ethical approval was obtained from the Royal Brompton and Harefield
NHS Trust and National Heart and Lung Institute NHS Research Ethics
Committee. Consecutive adult patients undergoing elective open thoracic
procedures likely to result in a postoperative air leak were considered for
the study. The heterogeneity of procedures was allowed to reflect clinical
practice. Patients of all 5 consultant thoracic surgeons undergoing opera-
tions between December 2005 and December 2007 at the Royal Brompton
Hospital were considered for the study. Informed written consent was
obtained from patients before surgery. Exclusion criteria included age less
than 18 years, pregnancy, breastfeeding, previous treatment with BioGlue
or Vivostat on the same operative side, inability to give informed consent,
pneumonectomy, empyema, and absence of air leak at the conclusion of
the pulmonary resection.
Preparation and Application of Sealants
The Vivostat system is an automated device for the perioperative prepa-
ration of an autologous fibrin sealant. An amount of 120 mL of the patient’s
blood was obtained via a previously placed central venous cannula after tho-
racotomy and inspection of the lung in patients in whom operability was
confirmed and pneumonectomy was not required. Blood was collected
into the citrate-containing preparation unit. The preparation unit was then
placed within the processor unit. Processing occurred in approximately
25 minutes and resulted in an autologous fibrin solution titrated to the
patient’s own fibrinogen levels. The fibrin solution was placed in the appli-
cation unit together with the pH-activating solution. After priming of the
application unit and confirmation of admixture on litmus testing, the sealant
was applied with a hand-held spray-pen device. Two minutes were allowed
before insufflation of the lung to allow polymerization. BioGlue is a surgical
adhesive composed of solutions of bovine serum albumin and glutaralde-
hyde within a double-chambered syringe and applicator tip.11
Randomization
Adecision to prepare the sealant was made by the operating surgeon after
inspection of the lung. A decision to randomize the patient was taken by the
consultant surgeon when conventional attempts (sutures, stapling, or dia-
thermy) to control the air leak failed. Randomization was via a closed enve-
lope system in permuted blocks of 6, with stratification for grade of air leak.
Intervention
After completion of each operation, the thoracic cavity was filled with
warm saline (benign pathology) or water (malignant pathology), and the
lung was insufflated to 25 cm water pressure to establish the presence or
absence of parenchymal air leak. Control of any air leak was attempted
using stapling, diathermy, or sutures. Air leaks not controlled by such mea-
sures were stratified according to grade of air leak. Classification was as
follows: grade 1, minimal air leak; grade 2, easily visualized air leak but
not considered large; grade 3, large air leak. Randomization according to
grade was performed. Fluid was evacuated from the chest cavity, the lung
was collapsed, and relevant surgical sealant was applied. In the case of Bio-
Glue, as many applications were used as necessary for control of the leak.
Further applications of Vivostat were allowed if necessary until the prepared
solution was exhausted. Application of either sealant to the bronchial stump
or anastomosis was avoided. Further insufflation of the lung was delayed for
2 minutes to allow polymerization to occur. Patients received either anteriorThe Journal of Thoracic and Cand posterior apicobasal drains or a single posterior apicobasal drain (24F–
32F). Drains were placed on underwater seal drainage with or without
suction according to surgeon protocol. Patients with a persistent air leak
had conversion to a Heimlich system and were discharged when clinically
appropriate.
Air leaks were defined as the expulsion of more than 1 bubble visualized
in the underwater seal drain or palpation of air through the valve of
a Heimlich system. Postoperative air leaks were recorded by the surgical
team each day, who were not blinded to the randomization process. Suction
was generally reserved for patients in whom the lung failed to fully expand.
It was the protocol of 1 surgeon to place drains on underwater seal with suc-
tion until the first postoperative day (POD). The criteria for chest drain
removal remained at the discretion of the consultant surgeon in charge of
the individual patient; however, in general, drains were removed within
24 hours of cessation of air leak and when the drainage was less then 200
mL per 24 hours. Patients were followed until discharge or removal of
the final drain, whichever was the latter event. For the purposes of statistical
analysis, air leaks in patients with conversion to a Heimlich system were
considered to persist until drain removal.
Statistical Methods
The primary outcome measures were proportion of patients with drains
removed on or before POD 3, duration of air leak, length of intercostal
drainage, and hospital stay. Secondary outcome measures related to other
complications. Comparisons were made using t tests for normally distrib-
uted data, Mann–Whitney tests for non-normally distributed measures,
and Fisher’s exact test for proportions. Time to event data were analyzed
by Kaplan–Meier analysis and compared using the Peto test.
Sample Size Calculation
In a previous study5 conducted at the Royal Brompton Hospital, it was
found that 84% of patients receiving BioGlue had chest drains removed
on or before POD 3. To show a 15% difference between those receiving
BioGlue and those receiving the Vivostat sealant, with a significance of
0.05% and a power of 0.8, a sample size of 102 was estimated (51 in each
arm). An interim analysis was planned at the halfway point of the study.RESULTS
Patients and Operations
Between December 2005 and December 2007, 378 pa-
tients were eligible for inclusion in the study. Nine patients
declined to participate. Seventeen patients did not consent
because of unavailability of either the patient or interpreter.
A total of 352 patients consented to participation in the
study. Six patients underwent pneumonectomy, and 240 pa-
tients had no air leak after surgery or conventional means of
control. One patient did not proceed to thoracotomy and re-
section after a positive mediastinoscopy. In 2 patients, lack
of available staff to prepare Vivostat sealant prevented inclu-
sion. Therefore, 103 patients were randomized (Figure 1).
One patient was excluded from the study because of air
leak from bronchial tear with no associated parenchymal
air leak at re-thoracotomy. Sixty-seven percent of patients
were male, and the median age was 56  19 years. Indica-
tions for surgery were primary lung cancer in 41 patients
(40%), secondary malignancy in 48 patients (47%), carci-
noid tumor in 6 patients (6%), and benign disease in
7 patients (7%). Bilobectomy was performed in 2 patients
(2%), lobectomy was performed in 41 patients (40%),ardiovascular Surgery c Volume 140, Number 1 33
FIGURE 1. Consort diagram.
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(3%), segmentectomy was performed in 16 patients (16%),
precision excision was performed in 34 patients (33%), and
6 patients underwent other resections (6%). Two patients
underwent an exploratory thoracotomy without lung resec-
tion, 1 patient underwent a bronchial sleeve resection, 1 pa-
tient underwent thoracotomy and tumor biopsy, and
2 patients underwent resection of mediastinal masses adher-
ent to lung parenchyma, 1 of whom also underwent decorti-
cation of the right lung. Four patients underwent extended
resection. Three patients underwent diaphragmatic resection
(2 patients in the Vivostat group and 1 patient in the BioGlue
group). One patient in the BioGlue arm of the study under-
went a chest wall resection. Preoperative spirometry was
available for 95 of 102 patients. Median forced expiratory
volume at 1 second was 2.63 L (range, 1.14–4.67 L) for
the BioGlue group and 2.86 L (range, 1.26–4.5 L) for the
Vivostat group (P ¼ .443). Forced expiratory volume at
1 second/forced vital capacity ratio was 76.6% (range,
48.7%–95.7%) for the BioGlue arm and 75.65% (range,
48%–94.4%) for the Vivostat arm of the study (P ¼ .463).
Fifty patients were randomized to receive BioGlue, and
52 patients were randomized to receive Vivostat. Patient de-
mographics were compared between the 2 groups (Table 1).
No significant differences were found with the exception
that there were more men in the Vivostat arm compared34 The Journal of Thoracic and Cardiovascular Surgewith the BioGlue group (77% vs 56%, P ¼ .035). More
redo operations occurred in the BioGlue arm, but this was
not significant. All patients in the BioGlue arm received
one 5-mL pack of BioGlue except 1 patient who received
2 packs. It was not possible to achieve optimum Vivostat ap-
plication on 6 occasions. Sealant was applied in 4 cases and
not applied in the remaining 2 instances. All 6 patients were
included in an intention-to-treat analysis. A further per-
protocol analysis excluding these 6 patients from the Vivo-
stat arm of the study was conducted. Thirty-three patients
received 1 intercostal drain, 68 patients received 2 intercos-
tal drains, and 1 patient received 3 drains.
Primary Outcome Measures
After application of sealant, air leak was completely con-
trolled in 16 of 50 patients (32%) in the BioGlue group and
17 of 52 patients (33%) in the Vivostat group. The median
duration of air leak for patients receiving BioGlue was
3 (0–32) days compared with 2 (0–33) days for those
patients receiving Vivostat (P ¼ .677). Median duration of
intercostal drainage was 5 (1–32) days for the BioGlue arm
and 5 (1–34) days for patients in the Vivostat arm of the study
(P ¼ .473). Median duration of hospital stay was 8 (3–22)
days for patients receiving BioGlue versus 7 (2–29) days
for those receiving Vivostat (P¼ .382) (Table 2). The propor-
tion of patients with drains removed on or before POD 3 wasry c July 2010
TABLE 1. Patient demographics
BioGlue
(CryoLife, Europa
Ltd, Surrey, UK)
arm (n ¼ 50)
Vivostat
(Vivostat A/S,
Alleroed, Denmark)
arm (n ¼ 52) P value
Mean age (y),
n (range)
57 (18–78) 56 (18–87) .908
Male, n (%) 28 (56) 40 (77) .035
Reoperation, n (%) 10 (20) 4 (8) .088
Procedure, n (%)
Bilobectomy 1 (2) 1 (2)
Lobectomy 19 (38) 22 (42) .690
Lobectomy with
lesser resection
2 (4) 1 (2)
Segmentectomy 7 (14) 9 (17)
Precision excision 20 (40) 14 (27)
Other 1 (2) 5 (10)
Diagnosis, n (%)
Primary lung
cancer
21 (42) 20 (38)
Secondary
malignancy
26 (52) 22 (42) .428
Carcinoid 0 (0) 6 (12)
Benign 3 (6) 4 (8)
Severity of air leak,
n (%)
Mild 34 (68) 33 (63) .680
Moderate 14 (28) 17 (33)
Severe 2 (4) 2 (4)
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patients (29%) in the Vivostat arm of the study (P ¼ .5).
A per protocol analysis was performed on patients who
received optimally prepared sealants. Six patients in the
Vivostat arm of the study were excluded. The median dura-
tion of air leak for patients receiving BioGlue was 3 (0–32)
days compared with 2 (0–33) days for those patients receiv-
ing Vivostat (P ¼ .594). The median duration of intercostal
drainage was 5 (1–32) days for the BioGlue arm and
5 (1–34) days for patients in the Vivostat arm of the study
(P ¼ .452). Median duration of hospital stay was 8 (3–22)
days for patients receiving BioGlue versus 7 (2–29) days
for those receiving Vivostat (P ¼ .390).
Observed Complications
Overall, complications occurred in 20 patients (40%) in
the BioGlue arm and 19 patients (37%) in the VivostatTABLE 2. Primary outcome measures
BioGlue arm
(n ¼ 50)
Vivostat arm
(n ¼ 52) P value
Duration of air leak (d) 3 (0–32) 2 (0–33) .677
Duration of intercostal drain (d) 5 (1–32) 5 (1–34) .473
Duration of hospital stay (d) 8 (3–22) 7 (2–29) .382
Data in parentheses represent range. Results expressed as median with range. P values
obtained using Mann–Whitney test.
The Journal of Thoracic and Carm (P ¼ .839). There were no deaths. Complications
were considered in 3 categories: prolonged air leak, pleural
space infection, and others. Nine of 50 patients (18%) and
12 of 52 patients (23%) had prolonged air leak in the Bio-
Glue and Vivostat groups, respectively (P ¼ .627). Seven
patients in each arm underwent conversion to a Heimlich
system and 4 patients (8%) in the BioGlue arm and 5 pa-
tients (10%) in the Vivostat arm were discharged with
a Heimlich system (P ¼ 1.000) (Table 3).
The incidence of clinical pleural space infection was 4 of
50 patients (8%) in the BioGlue arm of the study and 1 of 52
patients (2%) in the Vivostat arm (P¼ .2). Of the 4 patients
in the BioGlue group who experienced clinically infected
pleural spaces, 1 patient, initially discharged on POD 5,
was readmitted 4 days later with a methicillin-resistant
Staphylococcus aureus empyema and underwent re-thora-
cotomy and decortication on POD 18. Length of stay after
readmission was 13 days. A coagulase-negative Staphylo-
coccal empyema developed in 1 patient (initially discharged
on POD 10) on POD 40, requiring readmission, drain inser-
tion, and antibiotics. Readmission length of stay was 13
days. The drain was finally removed 120 days postinsertion.
Enterococcus faecalis empyema was observed on POD 9 in
a patient with diarrhea requiring antibiotics and drainage un-
til POD 17, but not reoperation. Length of hospital stay for
this patient was 19 days. A culture-negative loculated effu-
sion and pyrexia on POD 30 were treated with readmission,
drainage, and antibiotics for 5 days in 1 patient. In the Vivo-
stat arm, methicillin-resistant S aureus empyema developed
in 1 patient on POD 11 requiring urgent re-thoracotomy and
decortication. Hospital stay for this patient was 20 days.
In the BioGlue arm, 7 patients experienced other compli-
cations. These included readmission to the intensive care
unit for hypotensive management in a patient with a dilated
cardiomyopathy and a thoracic epidural. Acalculous chole-
cystitis and hepatorenal impairment occurred in 1 patient.
Acute on chronic renal impairment and lobar collapse
requiring fiberoptic bronchoscopy were observed in 1 pa-
tient, and sputum retention requiring rigid bronchoscopy
was observed in 1 patient. Nerve palsies of the recurrent
laryngeal, radial, and ulnar nerves complicated the postoper-
ative course of 1 patient, and pneumothorax post-drain
removal requiring drain reinsertion occurred in 1 patient.
Clostridium difficile infection complicated the postoperative
course of 1 patient.
Complications developed in 6 patients in the Vivostat
group.Wound dehiscence developed in 1 patient, and pyelo-
nephritis developed in 1 patient. Reoperation for ruptured
bulla on POD 14 was necessary in 1 patient. Chest infection
and sputum retention occurred in 1 patient, and pneumotho-
rax after drain removal not necessitating further drain inser-
tion occurred in 1 patient. Atrial fibrillation, renal
impairment not requiring hemofiltration, gastrointestinal
bleeding, and pseudo-obstruction developed in 1 patient.ardiovascular Surgery c Volume 140, Number 1 35
TABLE 3. Secondary outcome measures
BioGlue arm (n ¼ 50) Vivostat arm (n ¼ 52) P value
Prolonged air leak, n (%) 9 (18) 12 (23) .627
Pleural space infection, n (%) 4 (8) 1 (2) .200
Conversion to Heimlich system, n (%) 7 (14) 7 (13) 1.000
Discharge with Heimlich system, n (%) 4 (8) 5 (10) 1.000
Complications excluding prolonged air leak, n (%) 11 (22) 7 (13) .305
Overall complications, n (%) 20 (40) 19 (37) .839
Clinical or culture-positive pleural space infection, n (%) 9 (18) 6 (12) .411
Results expressed as number of cases (percentage of group). P values obtained using Mann–Whitney test.
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This study demonstrated no difference in the efficacy of
the 2 surgical sealants, BioGlue and Vivostat, in the control
of postoperative air leak. A systematic review12 of trials of
sealants for the prevention of air leak10,13-20 concluded
that systematic use could not be recommended, because
only 1 trial demonstrated a reduction in the duration or inci-
dence of prolonged air leak.14 However, these studies repre-
sent a heterogeneous group of trials, examining a variety of
products, including fibrin-based sealants,14,15,17,20-23 poly-
ethylene glycol-based products,13,16,18,19 and autologous
sealants.10 In only 3 trials was randomization after confirma-
tion of air leak probably leading to the predominantly nega-
tive outcome seen in most of the trials.
More recently, a trial at the Royal Brompton Hospital
examined the efficacy of BioGlue in the management of air
leak in patients in whom air leak was not controlled by con-
ventional surgical means.5 This was the first trial to show
significant differences in all 3 clinically relevant end points
of duration of air leak, time to intercostal drain removal,
and time to discharge.5 A further study using TachoSil
(Nycomed, Linz, Austria) also showed significant benefit at
all 3 clinical end points in a similar population of patients.24
Despite the clear benefits of BioGlue,5 concerns exist re-
garding the safety of animal and chemically based sealants.
Its bovine derivation raises the possibility of blood-borne
disease transmission. Its 2-year absorption time and non-
autologous nature may theoretically predispose to infection,
and spillage onto airway stumps may cause bronchopleural
fistula.6,8 Moreover, its rigid, inelastic nature does not ex-
pand with the underlying lung, and this may result in shear-
ing of the sealant resulting in reappearance of previously
controlled air leak. Indeed, in our previous study, post-drain
removal pneumothoraces were observed in 3 patients in the
BioGlue arm, 1 of whom required intercostal drain insertion.
The autologous nature of Vivostat reduces the potential for
foreign body reaction and does not carry the generic con-
cerns associated with bovine products. The Vivostat system
produces a sealant that has superior elastic properties and
a faster absorption time of approximately 50% resorption
within 5 days in animal models.9 We therefore sought
to compare BioGlue with Vivostat. Should Vivostat prove36 The Journal of Thoracic and Cardiovascular Surgeto be as efficacious as BioGlue, then its inherent advantages
could commend its use.
The present study is the first randomized controlled trial to
compare 2 sealants in the reduction of air leak after lung
resection. The present study suggests that Vivostat is not
inferior to BioGlue in the control of postoperative air leak.
Our results concur with a previous smaller study comparing
Vivostat with a non-treatment control that found a statisti-
cally significant reduction in the incidence of air leak in
the treatment group.10
We also sought to examine as secondary end points the
incidence of postoperative complications. Because post-
lobectomy empyemas are most commonly associated with
prolonged air leaks,25 the efficacy of such sealants in the
reduction of air leak might translate into a reduction in the
incidence of postoperative empyema. However, concerns
exist that application of sealants may actually predispose
to empyema.8,10
The incidence of clinical pleural space infectionwas 8% in
the BioGlue arm and 2% in the Vivostat arm, which did not
reach conventional levels of significance. The incidence of
clinical space infection of 2% in the Vivostat group is com-
parable to that of previously published series of postoperative
empyema rates after lobectomy,26-29 and although not signif-
icantly higher, an incidence of 8% in the BioGlue groupmay
be described as high. Nine previous sealant trials have shown
only nonsignificant differences in the rates of postoperative
empyema. There were no cases of empyema in 5 tri-
als.5,13,14,21,24 There was an incidence of 3% versus 0% in
favor of the treatment group in 1 trial.22 Cases of empyema
were found only in the treatment groups in 3 trials.16,18,19
In the trial by Porte and colleagues,18 localized empyema
developed in 4 patients, requiring drainage of the infected
sealant. Macchiarini and colleagues16 reported 1 patient in
the treatment group who required completion pneumonec-
tomy after postoperative empyema, and Wain and col-
leagues19 also reported postoperative empyema developing
in 1 patient in their treatment group. Infection of the pleural
space is a secondary outcome, and our trial was not powered
to study this issue; however, it suggests, in line with previous
studies,16,18,19 that the use of sealants is not associated with
a reduction in the incidence of postoperative empyema, andry c July 2010
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a demonstrable air leak at completion of the operation.
The cost implications of the use of either sealant are not
significantly different. BioGlue costs approximately $498
per 5-mL packet, compared with approximately $462 per ap-
plication for Vivostat. The nondisposable equipment is
available on loan from the manufacturing company, but an
operator is required to collect and process the sealant.
An inherent disadvantage of the Vivostat system is the
time taken to prepare the product. We recommend that the
decision to prepare the Vivostat sealant is taken after assess-
ment of resectability and inspection of both fissure and
parenchyma to evaluate the risk of air leak. This will mini-
mize the waste of blood and Vivostat sealant components
while not increasing operative time.
It was not possible to achieve optimum Vivostat applica-
tion on 6 occasions. This occurred early in the study and was
probably related to poor technique in terms of acquisition
and processing of blood. Although this is probably correct-
able with training and experience, it reflects the additional
technical nature of the Vivostat system.
The main strength of this study is its prospective, random-
ized nature. The heterogeneity of our study because of the
inclusion of reoperations and multiple surgeons reflects
real-world clinical practice. A limitation of the study is
that it is powered as a non-inferiority study rather than an
equivalence trial, which would require a long-term, large
scale, multicenter study.
The percentage of chest drains removed by POD 3 in the
patients treated with BioGlue during the previous study was
84%. This was used to estimate the sample size for the cur-
rent trial. However, in the present study in a similar group of
patients, the proportion of patients with drains removed on or
before POD 3 was 11 of 50 patients (22%) in the BioGlue
arm. This discrepancy may have important ramifications
for sample size. Although these differences may reflect var-
iations in patient populations over time, it is possible that this
may also be accounted for by the following explanations.
In the interstudy interval, there has been a reduction in the
use of negative pressure suction to the underwater seal in the
postoperative setting. During the first trial, 5 kPa negative
pressure suction was applied, continuing until any air leaks
ceased and drains removed 24 hours later if no further air
leaks were present. Currently, 4 surgeons reserve suction
for those patients in whom the lung will not inflate. The re-
maining surgeon places 5 kPa of negative pressure at the end
of each case until the first POD, in the absence of air leak at
the time. Because the use of suction has been suggested to
increase the duration of postoperative air leak, this change
of policy should not account for the reduction in proportion
of patients with drains removed by the third POD.
In the previous study, there were, by chance, a greater
number of segmentectomies, fewer precision excision meta-
stasectomies, and more severe air leaks in the control arm,The Journal of Thoracic and Cwhich may favor a longer duration of air leak in the non-
intervention group. However, the demographics of the
2 groups were well matched overall. We have 5 surgeons
in the current trial compared with 2 surgeons in the previous
study, which may have contributed to the discrepancy be-
tween the 2 studies.
CONCLUSIONS
Because Vivostat is not inferior to BioGlue, previously
shown by the Royal Brompton Hospital to significantly re-
duce postoperative air leak, we recommend its use in the
management of air leak after lung resection because of its in-
herent advantages. Because concerns remain regarding the
use of surgical sealants and infection, we would caution
against routine use of sealants and recommend that use
should be restricted to those patients in whom air leak per-
sists after conventional intraoperative techniques have failed
and the patient is thought to be at risk of prolonged postop-
erative air leak.
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